A research group led by Assistant Professor Megumi Aimoto and Professor Akira Takahara at the Faculty of Pharmaceutical Sciences, Toho University, revealed that pyrazole-3 (Pyr3), a selective inhibitor of the transient receptor potential canonical-3 (TRPC3) channel, a calcium-permeable channel in the heart, prevents the persistence of atrial fibrillation. Atrial fibrillation is a tachyarrhythmia that occurs in the atria and is a major cause of stroke and heart failure. This study demonstrated that the TRPC3 channel is a promising new therapeutic target for atrial fibrillation.
This article was originally published on MedicalXpress.com
